---
title: Lilly Will Pay Up to $1.5 Billion for Calytrix's Blood Cancer Antibody, Months After Its $2.3 Billion Ajax Deal
description: Eli Lilly is buying Calytrix Bio, a 2025 J.P. Morgan start-up with an untested mutant CALR antibody, while Incyte's rival drug is already in Phase 3.
author: Darie Nani (Editor-in-Chief)
date: 2026-11-17T12:59:37.759Z
updated: 2026-11-17T12:59:37.774Z
canonical: https://www.sovereignmagazine.com/article/lilly-calytrix-bio-acquisition-mutant-calr
image: https://cdn.nanimediahouse.com/pexels-scientist-wearing-face-mask-and-goggles-examining-samples-th-4033151.jpg
categories: Business
content_type: News
region: United States
publication: Sovereign Magazine
schema_type: Article
about:
  - type: Organization
    name: Calytrix Bio
    description: Privately held Wellesley Hills, Massachusetts biotech developing antibody therapies against mutant calreticulin for myeloproliferative neoplasms.
    url: https://calytrixbio.com
  - type: Organization
    name: Eli Lilly
---

Eli Lilly has agreed to buy Calytrix Bio, a Wellesley Hills, Massachusetts, biotech founded in 2025, for up to $1.5 billion in cash. Calytrix's lead program is an antibody against mutant calreticulin, or mutant CALR, for essential thrombocythemia and myelofibrosis, two blood cancers in the family known as myeloproliferative neoplasms (MPNs). The antibody has not yet been tested in people.

The $1.5 billion is made up of an undisclosed upfront payment and later payments due when the program reaches certain clinical and regulatory milestones. Neither a closing date nor a start date for the first human trial has been given.

Calytrix was set up by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm of J.P. Morgan Asset Management, which co-led its Series A with Westlake BioPartners. Avoro Ventures led a Series B. Calytrix has not said how much either round raised.

## Calytrix Designed Its Antibody to Target Both Type 1 and Type 2 CALR Mutations

Calytrix says current drug therapies for essential thrombocythemia and myelofibrosis "primarily manage symptoms and complications." The company describes mutant CALR as a target found on the surface of the cancer cells and not on healthy tissue, and says a drug aimed at it has the potential to clear the mutant cells that drive the disease while sparing normal ones. Its antibody is designed to hit both Type 1 and Type 2 CALR mutations, which the company calls "pan-mutant activity."

"Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, Calytrix's president and chief executive. Prosek says the company's goal from the start has been "to alter the disease course in mCALR-driven ET and MF."

## Lilly Agreed in April to Pay Up to $2.3 Billion for Ajax Therapeutics

On April 27, Lilly agreed to buy Ajax Therapeutics, another developer of MPN drugs, for up to $2.3 billion in cash, also split between an undisclosed upfront payment and milestone payments.

Ajax's lead drug, AJ1-11095, is a once-daily pill in a class Ajax calls Type II JAK2 inhibitors. The companies say every approved JAK2 inhibitor for MPNs binds the Type I form of the JAK2 protein, and that many patients stop taking those drugs because the benefit does not last or they stop responding. AJ1-11095 has been in a Phase 1 trial since late 2024, in people whose earlier myelofibrosis treatment was a Type I JAK2 inhibitor, and the companies said in April that the first proof-of-concept data were due later in 2026.

"As a founding strategic investor in Ajax, Lilly has long believed in the approach," Jacob Van Naarden, executive vice president, president of Lilly Oncology and head of corporate business development, said in April.

Across the two agreements, Lilly could pay up to $3.8 billion for two different approaches to the same group of blood cancers: a pill aimed at JAK2 and an antibody aimed at mutant CALR.

## Incyte Started a Phase 3 Trial of Its Mutant CALR Antibody in September

Incyte already has human data for its own mutant CALR antibody, INCA033989, which it calls "first-in-class." At the American Society of Hematology meeting in December 2025, Incyte reported early Phase 1 results in myelofibrosis patients with a CALR mutation: at Week 24, 12 of 36 evaluable patients treated with INCA033989 alone, or 33.3%, had their spleen volume reduced by at least 35%. Incyte said those results built on "positive results previously reported in essential thrombocythemia," and that it planned to start a registrational program in myelofibrosis, the trials meant to support approval, in 2026.

Incyte's Phase 3 trial in essential thrombocythemia, EXCALIBUR-ET2, [began on September 8, 2026](https://clinicaltrials.gov/study/NCT07623200) and aims to enroll about 426 people with a CALR mutation who have already been treated with drugs that lower blood cell counts. It compares INCA033989 with the treatment each patient's trial doctor would otherwise choose, and its primary completion is estimated for June 2029.

## Galecto and Janssen Are Also Testing Drugs Against Mutant CALR

Galecto completed its purchase of Damora Therapeutics, a private company developing antibodies against mutant CALR, on November 10, 2025, and raised $285 million in a private investment at the same time. Galecto calls Damora's lead antibody, DMR-001, "a potentially best-in-class monoclonal antibody targeting mutCALR," and expects Phase 1 proof-of-concept data in 2027.

Janssen Research & Development has been running a first-in-human study since December 2023 of JNJ-88549968, which the trial record describes as "a T-cell redirecting bispecific antibody for CALR-mutated myeloproliferative neoplasms." The study's primary completion is estimated for June 2027.

## FAQ

**Q: Has Damora's mutant CALR antibody started human trials?**
Damora's Phase 1/1b study tests its mutant calreticulin antibodies on their own or with ruxolitinib in people with CALR-mutant myeloproliferative neoplasms. It is recruiting, with an estimated start of September 2026 and about 250 participants planned.

**Q: Who advised on the Calytrix deal?**
Centerview Partners is Calytrix's exclusive financial adviser and Goodwin Procter is its legal counsel. Paul, Weiss, Rifkind, Wharton & Garrison is Lilly's legal counsel.

**Q: How is INCA033989 given?**
Intravenously. In Incyte's randomized, open-label Phase 3 trial in essential thrombocythemia, patients in the comparison group receive best available therapy chosen by the investigator, which could include hydroxyurea, anagrelide, PEG interferon alfa-2a or ropeginterferon alfa-2b. The trial's main measure is a durable response at Week 24, defined as normal platelet and white blood cell counts with no disease progression.
